



Spermosens receives patent approval in Israel

Spermosens AB ("Spermosens" or the "Company") today announces that the patent "*Biosensor for Male Infertility*" (IL 280445) has been granted in Israel. The patent covers the company's unique method for measuring sperm binding to the egg receptor JUNO, a critical biological interaction during fertilization that no existing test can evaluate.

The granted patent in Israel strengthens Spermosens' intellectual property portfolio, which already includes patents in key markets such as Europe, the United States, Japan, South Korea, Australia, South Africa, Hong Kong, Singapore, Canada, and Mexico. The protection covers both the method and system underlying the JUNO-Checked technology, providing long-term exclusivity for the company's approach to assessing critical sperm function.

Tore Duvold, CEO of Spermosens, comments: *"The granted patent in Israel is an important step for our global IP coverage. JUNO Checked is unique in its ability to directly measure sperm-egg interaction, something conventional tests cannot assess, and Israel is a strategically important market due to its strong life science sector and advanced fertility care."*

About JUNO-Checked

JUNO-Checked is a patented diagnostic technology developed by Spermosens to assess the ability of sperm cells to bind to the JUNO receptor on the egg — a crucial step in fertilization. This interaction cannot be evaluated with conventional semen analysis. By replicating this process in vitro, JUNO-Checked provides a functional measurement of sperm-egg binding, offering new insight for the assessment of male fertility.

For further information, please contact:

Tore Duvold, CEO

Email: info@spermosens.com

Spermosens AB is a pioneering biotechnology company based in Sweden, focused on advancing fertility diagnostics through science driven solutions. The company develops cutting edge technologies designed to improve fertility outcomes and streamline treatment pathways for individuals and couples facing infertility. The proprietary product, JUNO-Checked, provides a novel diagnostic approach that enhances precision and evaluations by measuring the sperm egg binding capacity. JUNO-Checked supports more informed clinical decisions and individualized treatments strategies. Driven by a strong commitment to scientific excellence and patient care, Spermosens collaborates with leading research institutions to deliver transformative fertility diagnostics to the global market. The company's shares are listed on the Spotlight Stock Market under the name SPERM (ISIN code SE0015346424). For more information, see www.spermosens.com